Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Crig antagonists

An antagonist, antibody technology, applied in the direction of antiviral agent, antifungal agent, antibacterial agent, etc., can solve the problem of unclear effect and so on

Inactive Publication Date: 2010-03-17
GENENTECH INC
View PDF45 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In vivo, the role of KC-expressed CR3 in binding iC3b-coated pathogens is less clear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Crig antagonists
  • Crig antagonists
  • Crig antagonists

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0078] Preparation of anti-CRIg antagonistic antibody

[0079] (i) Antigen preparation

[0080] Soluble antigens or fragments thereof, optionally conjugated to other molecules, can be used as immunogens to generate antibodies. For transmembrane molecules, such as receptors, fragments thereof (eg, extracellular domains of receptors) can be used as immunogens. Alternatively, cells expressing transmembrane molecules can be used as immunogens. Such cells may be derived from natural sources such as cancer cell lines, or may be cells transformed by recombinant techniques to express transmembrane molecules. Other antigens and forms thereof useful for preparing antibodies will be apparent to those skilled in the art.

[0081] (ii) Polyclonal Antibody

[0082] Polyclonal antibodies are preferably raised in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections of the relevant antigen and adjuvant. Using bifunctional or derivatizing reagents such as maleimidoben...

Embodiment 1

[0179] Example 1: Generation of monoclonal antibodies against muCRIg and huCRIg-short

[0180] Monoclonal antibodies against murine CRIg (muCRIg) were generated by 11 injections of monophosphoryl lipid A / dicorylate in the footpads of B6 (KO) mice Jam46E3 (Genentech, Inc.) 2 μg of immunoadhesin mouse (mu) CRIg-mFc (PUR 9465, mouse CRIg fused to the C-terminal Fc portion of mouse IgGl ) in thehalose dicorynomycolate adjuvant (Corixa, Hamilton, MT). Popliteal lymph nodes from mice were fused with P3X63Ag.U.1 (ATCC #CRL-1957) myeloma cells. Hybridoma cells were screened for binding affinity to muCRIg using muCRIg-LFH (PUR 9052, mouse CRIg conjugated to a leucine zipper, flag and (8x) histidine tag). Antibody-producing cell lines were cloned by limiting dilution.

[0181] In another study, monoclonal antibodies against muCRIg and huCRIg-short (huCRIg-short) were generated by 11 injections of monophosphoryl lipid A in the footpad of B6 (KO) mice Jam4 6E3 / 2 μg each of muCRIg a...

Embodiment 2

[0183] Example 2: Further characterization of monoclonal antibodies against muCRIg and huCRIg-short

[0184] Inhibition of iC3b binding to CRIg-expressing CHO cells incubated with anti-CRIg blocking antibody: 400,000 CHO cells were incubated with antibody for 25 minutes at 4°C and washed once. 5 μg / ml (27 nM) iC3b was added and incubated for 30 minutes at 4°C, washed and analyzed on a FACScan. The results are shown in Figure 6 .

[0185] Blocking of iC3b binding to CRIg+ peritoneal macrophages: Peritoneal cells were lavaged, centrifuged once and resuspended in 1% gelatin, 1 mM Ca ++ and 1mM Mg ++ (GVB ++ ) in Veronal buffer. Cells were incubated with or without endotoxin-free monoclonal antibodies (anti-CRIg mAb, clone 2H1, and isotype control). After 30 minutes of incubation, cells were incubated with different concentrations of A488-labeled iC3b (Advenced Research Technologies Inc.). Cells were then blocked for FcR-mediated binding (as described above) and stained ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention concerns blocking antibodies specifically binding a recently discovered macrophage specific receptor, CRIg, and their use to prevent cellular entry of intracellular pathogens, such as viruses, bacteria or parasites as well as for prevention of unwanted clearance of erythrocytes and platelets.

Description

field of invention [0001] The present invention concerns blocking antibodies that specifically bind to the recently discovered macrophage-specific receptor CRIg, and their ability to prevent intracellular pathogens such as viruses, bacteria, or parasites from entering cells and preventing unwanted clearance of red blood cells and platelets use. Background of the invention [0002] Complement system [0003] The complement system is a complex enzyme cascade composed of a series of serum glycoproteins that normally exist as inactive zymogens. Two main pathways, the classical pathway and the alternative pathway, which activate complement, merge at the level of C3, where two similar C3 convertases cleave C3 into C3a and C3b. [0004] Macrophages are specialized cells that have developed an innate ability to recognize small differences in the structure of signature tags expressed on the cell surface, so-called molecular patterns (Taylor et al., Eur J Immunol 33, 2090- 2097 (2...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28
CPCC07K16/2803C07K2316/96C07K2317/76A61P31/00A61P31/04A61P31/10A61P31/12A61P31/14A61P31/18A61P31/20A61P31/22A61P33/00C07K16/28C12N15/11
Inventor 门诺·范卢克伦坎佩恩
Owner GENENTECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com